In a secondary analysis of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, it was found that patients who achieved the highest reduction in high sensitivity CRP as a result of canakinumab treatment had better cardiovascular disease outcomes (63). The gene discussed is CRP; the disease is cardiovascular disorder.